Transnasal Catheter-Electrode

NerveStim Flex

Products Pain Management Neuromodulation NerveStim Flex
"Welcome, I want to help you. Customer Service "Thank you very much for your inquiry. We will get in touch with you as soon as possible."
Please select your country and I will find your next customer service."

NerveStim Flex Therapy

Sphenopalatine Ganglion (SPG) Stimulation to Treat Facial Pain and Headache

Clinical Challenges in Headache and Facial Pain Management

Every day, 15.8 % of the world’s population suffers from headaches, making headache disorders one of the most widespread and disabling diseases worldwide.1
Headache and facial pain are primarily treated with medications that may be associated with undesirable side effects, limitations in their dosage or contraindications.2

A therapeutic target for the treatment of facial pain and headache is the SPG. It is a paired parasympathetic ganglion located in the sphenopalatine fossa, receiving sensory, sympathetic, and parasympathetic fibers. Its connections to the trigeminal and facial nerves provide a convergence point for autonomic and nociceptive pathways, making it a potential target for both headache and facial pain modulation.3

SPG – A Convergence Point

Stimulation of the SPG can influence neural signal processing and is designed for modulation of pain transmission and associated autonomic symptoms, with potential results like: reduction of pain intensity, of autonomic symptoms and interruption of pathological reflex circuits.

Transnasal SPG stimulation is suitable for both inpatient and outpatient treatment, as it does not require implantation.

For the NerveStim Flex Therapy, PAJUNK® has developed both: the transnasal catheter-electrode NerveStim Flex that is designed for stimulation of the SPG and the NerveStim Neuro, a stimulation device for pain therapy.

Key Features of the NerveStim Flex Therapy

Medication-Free SPG Neuromodulation
Modulates the SPG through electrical stimulation without systemic medication administration, intended to reduce the need for analgesic medication and thereby also reduce the risk of potentially associated side effects.

Non-Surgically Invasive SPG Stimulation
Electrical stimulation of the SPG via a transnasal catheter-electrode, designed to modulate the SPG without associated surgical complications.

Individualized Therapy Application
Designed to enable patient-specific neuromodulation treatment in terms of therapy duration and frequency according to individual therapeutic needs.

Integrable into Multimodal Pain Therapy
Dual-modality transnasal catheter-electrode developed for delivery of either electrical stimulation or local anesthetic to the SPG.

With NerveStim Flex, the affected nerve structures like maxillary and palatine nerves or the pterygopalatine ganglion, which plays a role in the transmission, modulation and occurrence of pain can be targeted directly through the nose – completely non-invasively and without surgical risk.
Michał But, MD, PhD, DESA, EDPM
Specialist in Anesthesiology and Pain Management

NerveStim Flex Overview

NerveStim Flex Features & Advantages

Large Spherical Stimulation Head
  • Designed for an increased contact area at various contact angles.
One Lateral Opening

At 5 mm:

  • Enables alternative treatment with local anesthetics.
Stimulation Wire

Conducts the current to the stimulation head:

  • Intended to support kink stability. 
Depth Graduations

360° markings on the first 10 cm in 1 cm steps:

  • Indicates insertion depth of the NerveStim Flex in the nasal cavity.
  • Supports control of NerveStim Flex position.
Catheter-Electrode Design Features

Make the transnasal catheter-electrode soft and flexible:

  • Intends to prevent injury to the nasal mucosa.
  • Designed for easy advancement of the NerveStim Flex into the nasal cavity.
Extra Long Transnasal Catheter-Electrode
  • Developed for easy and comfortable fixation of the NerveStim Flex during stimulation.

NerveStim Flex Ordering Info

NerveStim Flex
Item description 20G x 300mm (12")
LUER
Item no. 		1142-10-300
NRFit®
Item no. 		1162-10-300
Purchase Unit 10

NerveStim Neuro

Studies:

1 Stovner L. J. et al. (2022). The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. The Journal of Headache and Pain, 23(1): 34.
2. Goadsby P. J. et al. (2019). Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial. The Lancet Neurology, 18: 1081–1090.
3. But M. et al. (2025). A Novel Method of Noninvasive Sphenopalatine Ganglion Stimulation in Craniofacial Pain: Case Series and Literature Review. Neuromodulation, 1–28.

NRFit® is a registered trademark of GEDSA and is used with their permission

Not all products are registered and approved for sale in all countries or regions. Indications of use may also vary by country and region. Please contact your country representative for product availability and information. Product images are for reference only.